Eisai and Alexa skills in epilepsy: the pharmaphorum podcastVoice technology like Amazon’s Alexa is taking some big steps forward in healthcare and in the pharmaceutical world Share XEisai and Alexa skills in epilepsy: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/eisai-alexa-skills-epilepsy/
FDA lets off Novartis after gene therapy data rowNovartis is off the hook following the FDA’s review of data manipulation in the filing of its hugely Share XFDA lets off Novartis after gene therapy data rowhttps://pharmaphorum.com/news/fda-lets-off-novartis-after-gene-therapy-data-row/
Shionogi and Tetra expand partnership ahead of Alzheimer’s trial readoutShionogi has expanded its partnership with its Alzheimer’s drug development partner Tetra Therapeutics, giving an option for a Share XShionogi and Tetra expand partnership ahead of Alzheimer’s trial readouthttps://pharmaphorum.com/news/shionogi-and-tetra-expand-partnership-ahead-of-alzheimers-trial-readout/
Biogen and Sangamo work on Parkinson’s and Alzheimer’s gene therapiesBiogen and Sangamo have begun a collaboration to develop gene regulation therapies for neurological diseases including Parkinson’s and Share XBiogen and Sangamo work on Parkinson’s and Alzheimer’s gene therapieshttps://pharmaphorum.com/news/biogen-and-sangamo-work-on-parkinsons-and-alzheimers-gene-therapies/
FDA approves ‘potential blockbuster’ migraine jab from LundbeckThe FDA has approved Lundbeck’s eptinezumab prophylactic treatment for migraine, the last from a gang of four drugs Share XFDA approves ‘potential blockbuster’ migraine jab from Lundbeckhttps://pharmaphorum.com/news/fda-approves-potential-blockbuster-migraine-jab-from-lundbeck/
Teva draws blank in phase 3 Tourette Syndrome trialTeva’s late stage trials of a potential drug for Tourette Syndrome have drawn a blank, just when the Share XTeva draws blank in phase 3 Tourette Syndrome trialhttps://pharmaphorum.com/news/teva-draws-blank-in-phase-3-tourette-syndrome-trial/
Warren Buffet shocks Wall Street with Biogen gambleBiogen is trying to resurrect two failed trials of its Alzheimer’s drug aducanumab – and superstar investor Warren Share XWarren Buffet shocks Wall Street with Biogen gamblehttps://pharmaphorum.com/news/warren-buffet-shocks-wall-street-with-biogen-gamble/
After rejection, NICE agrees to look again at migraine drug AimovigThe UK’s medicines cost-effectiveness agency NICE has agreed to look again at its decision to turn down NHS Share XAfter rejection, NICE agrees to look again at migraine drug Aimovighttps://pharmaphorum.com/news/nice-migraine-aimovig/
Novartis’ Mayzent EU approval offers SPMS patients new optionNovartis’ Mayzent has been approved in Europe for adults with secondary progressive multiple sclerosis (SPMS) and active disease. Share XNovartis’ Mayzent EU approval offers SPMS patients new optionhttps://pharmaphorum.com/news/novartis-mayzent-eu-approval-offers-spms-patients-new-option/
